Bulletin from the Annual General Meeting of Redsense Medical AB (publ) on May 28, 2025
Kommuniké från årsstämma i Redsense Medical AB (publ) den 28 maj 2025
Interim Report Q1 – January – March, 2025 Redsense Medical AB (publ.
Amendment: NOTICE TO THE ANNUAL GENERAL MEETING OF REDSENSE MEDICAL AB (PUBL)
Rättelse: KALLELSE TILL ÅRSSTÄMMA I REDSENSE MEDICAL AB (PUBL)
Rättelse av Redsense Medical AB (Publ.) årsredovisning 2024
Redsense Medical AB (Publ.
Changed date for publication of interim report Q1 2025
Clamp nears market lauch as summative evaluation review completed
NOTICE TO THE ANNUAL GENERAL MEETING OF REDSENSE MEDICAL AB (PUBL)
KALLELSE TILL ÅRSSTÄMMA I REDSENSE MEDICAL AB (PUBL)
Redsense Medical AB (publ) årsredovisning 2024
Bulletin from the Extra General Meeting of Redsense Medical AB (publ) on April 24, 2025
Kommuniké från extra bolagsstämma i Redsense Medical AB (publ) den 24 april 2025
EXTRAORDINARY GENERAL MEETING IN REDSENSE MEDICAL AB (PUBL)
EXTRA BOLAGSSTÄMMA I REDSENSE MEDICAL AB (PUBL)
Redsense updates on tariffs and Clamp
Interim Report Q4 – January – December, 2024 Redsense Medical AB (publ.
Redsense Medical reinforces team with new CFO and part-time support functions
Redsense Medical Board Member Malin Almgren has passed away
Preliminära siffror slog TradeVenues estimat
Redsense Medical announces strong closing of Q4 with net sales around 12,7 mSEK
VD-intervju med Sebastien Bollue på Redsense Medical
Redsense Medical announces completion of Clamp usability testing
Redsense Medical - Rapportkommentar Q3 2024
Interim Report Q3 – January – September, 2024 Redsense Medical AB (publ.
Redsense Medical to focus on core growth areas, discontinuing trading on OTCQX
Nomination committee appointed for the 2025 Annual General Meeting in Redsense Medical AB
Redsense Medical AB (publ) appoints a new CEO
Member of the board of Redsense Medical AB resigns
Chairman of the board of Redsense Medical AB resigns - Acting chairman of the board appointed
Interim Report Q2 – January – June, 2024 Redsense Medical AB (publ.
Major shareholding notification
Redsense has secured a new order worth MSEK 6.
The Board of Directors in Redsense Medical AB (publ) resolves to carry out a directed share issue of MSEK 7,5.
The CEO leaves Redsense Medical AB
Redsense Medical presents at Sedermeradagen Stockholm 2024
Redsense Medical Spotlight presentation at the 61[st] ERA Congress in Stockholm
Redsense Medical AB (publ) höll under onsdagen den 8 maj 2024 årsstämma varvid följande huvudsakliga beslut fattades.
Interim Report Q1 – January – March, 2024 Redsense Medical AB (publ.
Redsense Medical welcomes new investment from ShapeQ to accelerate growth
The Board of Directors in Redsense Medical AB (publ) ("Redsense" or the "Company") announces today that the Company’s Board of Directors, wi...
Redsense Medical attending Home Dialysis Congress in Germany
Uppdatering: Redsense Medical AB (publ) årsredovisning 2023, nu med bilagd årsredovisning i pdf
Redsense Medical AB (publ) årsredovisning 2023
Förtydligande: Redsense Medical AB (publ) upplyser att punkt 13 har omformulerats och att veckodagarna som datumen infaller på har uppdatera...
Home Dialysis Risk Prevention Act addressed in House Committee on Ways and Means Hearing
Redsense Medical presents at Redeye Theme: Commercialization in Life Science
Redsense Medical attending US dialysis conferences this spring
Meet Redsense Medical at the Swiss Nordic Bio 2024
Correction: Missing MAR-lable in previous press release - "Year-End Report – January – December, 2023 Redsense Medical AB (publ)"
Year-End Report – January – December, 2023 Redsense Medical AB (publ)
Redsense Medical presents at Stora AktiedagarnaStockholm
AAKP Says Medicare Should Prioritize Safety Innovation
Seventh Sense Adventures Holding AB to remain a long term investor in Redsense Medical AB
Appointment of new Chairman of Redsense Medical’s Board of Directors
Redsense Medical has received the sad news that the Chairman of the Board, Patrik Byhmer, has passed away.
Redsense Medical to present at the Life Science Investor Forum
Interim Report Q3 – January – September, 2023 Redsense Medical AB (publ)
Nomination Committee appointed for the 2024 Annual General Meeting of Redsense Medical AB
Redsense Medical to present at the Small Cap Growth Virtual Investor Conference
Redsense Medical AB’s shares to begin trading at OTCQX on September 29, 2023
Redsense Medical arranged Congressional Briefing to address Venous Needle Dislodgement
Interim Report Q2 – April – June, 2023 Redsense Medical AB (publ)
Redsense secures strong autumn with MSEK 11.2 order
Redsense Medical’s alarm system featured in KFF Health News
Redsense has submitted application for cross-trading at OTCQX Best Market in the US
Redsense to exhibit at the 60th ERA Congress Milan 2023
Redsense presents at Sedemeradagen Stockholm 2023
Kommuniké från årsstämma i Redsense Medical AB (publ) den 9 maj 2023
Interim Report Q1 – January – March, 2023 Redsense Medical AB (publ)
Home Dialysis Risk Prevention Act introduced by the US House of Representatives
Förtydligande: Redsense Medical AB (publ) upplyser om att sista anmälningsdag till årsstämman har förlängts till onsdagen den 3 maj 2023.
Redsense and the FDA held a Pre-Submission Meeting in Preparation for the 510(k) Premarket Submission for the Redsense Clamp
Redsense Medical AB (publ) årsredovisning 2022
Redsense presents at Stora Aktiedagarna Stockholm
Redsense Medical AB will present at the Life Science Day in Gothenburg on March 8
Year-end Report 2022 Redsense Medical AB (publ)
Top 10 Technology Hazards for 2023 includes Venous Needle Dislodgement
Redsense Medical reinforces the team with a new CFO
Partial delivery of record order
Styrelseledamot avgår på egen begäran
New order valued at 15.2 MSEK smashes previous company record
Correction: Consolidated cash flow analysis interim report January-September 2022 Redsense Medical AB (publ)
Interim Report Q3 – July – September, 2022 Redsense Medical AB (publ)
Valberedning utsedd inför årsstämman 2023 i Redsense Medical AB
Redsense receives highest value order to date
Redsense presents at Aktiedagen Lund
New article brings forward support for home dialysis in connection with comorbidities
Interim Report Q2 – April – June, 2022 Redsense Medical AB (publ)
Redsense announces CEO succession date
Redsense to exhibit on the 59[th] ERA-EDTA congress
Kommuniké från årsstämma i Redsense Medical AB (publ) den 2 maj 2021
Redsense announces new CEO
